BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Novartis AG Reports Strong Q2 Growth Fueled by Oncology Portfolio
Novartis AG Reports Strong Q2 Growth Fueled by Oncology Portfolio
17
2
BTCCSquare news:
Novartis AG delivered a robust Q2 performance, with Core EPS surging 24% to $2.42, exceeding analyst expectations. The pharmaceutical giant posted 11% constant-currency sales growth, powered by its oncology franchise including Kisqali (+64% globally) and Pluvicto, while facing headwinds in Cosentyx performance.
Operating margins expanded 340 basis points to 42.2%, demonstrating disciplined cost management. The company announced a $10 billion share repurchase program through 2027, signaling confidence in its financial position despite a 3.25% stock decline post-earnings.
By:
Previous
The Ultimate List of Provably Fair Crypto Games for Guaranteed Trust
Next
Kalp and CryptoTransact Partner to Integrate Web3 Payments with Real-World Assets
